Natixis Advisors L.P. Has $315.77 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Natixis Advisors L.P. increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 1.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,052,406 shares of the company’s stock after purchasing an additional 55,333 shares during the period. Novo Nordisk A/S makes up approximately 0.8% of Natixis Advisors L.P.’s holdings, making the stock its 13th largest position. Natixis Advisors L.P. owned 0.07% of Novo Nordisk A/S worth $315,770,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in NVO. Westside Investment Management Inc. increased its stake in Novo Nordisk A/S by 83.3% during the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after acquiring an additional 649 shares during the period. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD bought a new position in Novo Nordisk A/S during the third quarter valued at about $2,408,000. Lazard Asset Management LLC increased its stake in Novo Nordisk A/S by 182.2% during the third quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock valued at $135,883,000 after acquiring an additional 964,640 shares during the period. CENTRAL TRUST Co increased its stake in Novo Nordisk A/S by 111.6% during the third quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock valued at $546,000 after acquiring an additional 3,166 shares during the period. Finally, Ieq Capital LLC increased its stake in Novo Nordisk A/S by 136.6% during the third quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock valued at $2,498,000 after acquiring an additional 15,860 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on NVO shares. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets began coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Morgan Stanley began coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective on the stock. Finally, UBS Group began coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating on the stock. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Price Performance

NYSE NVO traded down $4.19 during trading hours on Thursday, reaching $125.02. 5,594,983 shares of the company’s stock were exchanged, compared to its average volume of 4,815,282. The stock has a market cap of $561.03 billion, a PE ratio of 46.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.43. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The firm has a fifty day moving average of $127.22 and a 200-day moving average of $112.70. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.